Reply from Authors re: Jack A. Schalken. Is Urinary Sarcosine Useful to Identify Patients With Significant Prostate Cancer? The Trials and Tribulations of Biomarker Development. Eur Urol 2010;58:19-20

摘要

There is no doubt that the metabolite-profiling study for prostate cancer (PCa) by Sreekumar et al. [1] represents a seminal approach in PCa research. However, one of the authors' conclusions about using sarcosine as a noninvasive urine-based PCa marker has been questioned, in part by our results [2]. We would like to thank Professor Schalken for bringing into focus some key aspects of the contradictory data of both studies and for pushing for consensus on how to design and execute biomarker studies [3]. His views inspire some additional comments and general considerations, despite the discussion of several points in the limitation section of our article [2].